Abstract
The potential prognostic value of GATA binding protein 3 (GATA3) in breast cancer has recently increased, although the evidence is inconclusive. This meta-analysis of 10 articles involving 5,080 breast cancer patients explored the prognostic and clinicopathological value of GATA3 in breast cancer. Time to tumor progression (TTP) and overall survival (OS) were primary endpoints. Pooled hazard ratio (HR), pooled risk ratio (RR), and 95% confidence interval (CI) were calculated to evaluate the association between GATA3, prognosis, and clinicopathological parameters. High GATA3 expression predicts breast cancer, with a HR (HR = 0.671; 95% CI = 0.475–0.947; P = 0.023) of TTP, but is not associated with OS (HR = 0.889; 95% CI = 0.789–1.001; P = 0.052). GATA3 overexpression is associated with positive ER (RR = 3.155; 95% CI = 1.680–5.923; P = 0.000), positive PR (RR = 3.949; 95% CI = 1.567–9.954, P = 0.004), lower nuclear grade (RR = 0.435; 95% CI = 0.369–0.514; P = 0.000), and smaller tumor size (RR = 0.816; 95% CI = 0.709–0.940; P = 0.005). High GATA3 expression may predict TTP in breast cancer, and such patients may show better clinicopathological features.
Highlights
Transcription factors or trans-acting factors are often organized in multigene families and play essential roles in activating target genes of specific cell fates by binding to their cognate DNA sequence to aid RNA polymerase II in locating the proper initiation site for transcription [1, 2]
Studies were selected for meta-analysis if they fulfilled the following criteria: (1) studies must have focused on breast cancer; (2) all patients must have had breast cancer diagnoses confirmed via pathological examination; (3) the expression level of GATA binding protein 3 (GATA3) protein must be analyzed in tumor tissues by immunohistochemical staining (IHC); (4) adequate data of pooled hazard ratios (HRs) and 95% confidence intervals (CIs); and (5) the correlation between GATA3 and clinicopathological features was discussed
Our results indicate that high expression of GATA3 is associated with an unfavorable prognosis and is a predictive factor associated with to tumor progression (TTP) in breast cancer patients but is not significantly associated with overall survival (OS)
Summary
Transcription factors or trans-acting factors are often organized in multigene families and play essential roles in activating target genes of specific cell fates by binding to their cognate DNA sequence to aid (and sometimes inhibit) RNA polymerase II (pol II) in locating the proper initiation site for transcription [1, 2]. The GATA family of transcription factors, which is composed of six highly conserved transcription factors, binds a consensus DNA sequence (A/T) GATA(A/G) in the promoters of target genes via two zinc-finger domains with the consensus sequence CX2CX17CX2C to directly activate or repress target gene expression [3]. GATA transcription factors play a wide role in determination of cell differentiation and control of cell proliferation and movement. GATA3 as a prognostic marker for breast cancer
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
